Africa HIV Treatment Drugs Market by Drug Class, Route of Administration, and Geography - Forecast and Analysis - 2023-2027

Published: Nov 2022 Pages: 150 SKU: IRTNTR74710

Africa HIV Treatment Drugs Market Forecast 2023-2027

The HIV treatment drugs market size in Africa is estimated to grow by USD 321.6 million at a CAGR of 3.76% between 2022 and 2027. The growth of the market depends on several factors, including the increasing prevalence of STDs, favorable international programs, and government collaborations. 

What will the Size of the Market During the Forecast Period?

To learn more about this report, Download the FREE Report Sample

Key Drivers, Trends, Challenges, and Customer Landscape

Our researchers studied the data for years, with 2022 as the base year and 2023 as the estimated year, and presented the key drivers, trends, and challenges for the market. Although there has been a decrease in demand for the market during the COVID-19 pandemic, a holistic analysis of drivers will help companies refine marketing strategies to gain a competitive advantage.   

Key Driver

The increasing prevalence of STDs is notably driving the market. STDs are caused by the transmission of different bacteria, viruses, and parasites due to the exchange of bodily fluids during sexual intercourse. STDs can affect both men and women. There are more than 30 different bacteria, viruses, and parasites that can cause STDs. HIV/AIDS is one such type of STD. Sub-Saharan Africa ranks first in the annual incidence of STDs when compared to other regions.

The increasing incidence and prevalence of STDs are spurring the demand for the screening, diagnosis, and treatment of HIV at the earliest to reduce the chances of mortality. Companies present across Africa are focusing on offering a wide range of treatment drugs to affected people. Hence, the increasing incidence and prevalence of STDs in several places are expected to foster the growth of the market during the forecast period.

Key Trend

The awareness campaigns conducted by various organizations are major market trends. The prevalence of STDs, such as HIV/AIDS, has increased in Africa. Thus, governments of different countries are taking initiatives to increase awareness of and funding for the development of new drugs to treat STDs. For instance, African countries such as Botswana, Cote d'Ivoire, the Democratic Republic of the Congo, Eswatini, Malawi, Rwanda, South Africa, and Nigeria provide strategic support to the CDC's Division of HIV/AIDS Prevention and communicate with various partners and stakeholders about HIV prevention methods, policies, and programs.

Similarly, the UNAIDS program of the UN is making vigorous efforts to end HIV AIDS being a public threat by 2030. It helps governments, the private sector, and communities by providing direction, consultancy, planning and coordination, and technical support to promote life-saving HIV services. Thus, the growing involvement of various organizations to increase awareness about HIV is expected to increase the demand for HIV treatment drugs and, in turn, fuel the growth opportunity for the market during the forecast period.

Key Challenge

The lack of diagnosis of HIV and access to modern medicines may impede the market. in Africa, there are still significant social and economic barriers that prevent people from being tested for HIV due to the fear of testing positive for HIV, which is seen as a stigma. Thus, some individuals are diagnosed with the disease for the first time only after they have been brought to the hospital following a seizure.

Caregivers are forced to either control seizures or treat the underlying HIV infection as the HIV infection has generally reached an advanced stage. Similarly, most African countries with high rates of HIV infection continue to rely largely on older antiepileptic drugs (AED) for seizure management, making HIV treatment less effective. Such factors may hinder the growth of the market during the forecast period.

Key Customer Landscape

Our analysis of the life cycle of the market indicates a movement from the innovator’s stage to the laggard’s stage. The market research and growth report illustrates the lifecycle of the market, focusing on the adoption rates of the major countries, including Uganda, Nigeria, and South Africa. Technavio's market forecasting report has included key purchase criteria, adoption rates, adoption lifecycles, and drivers of price sensitivity to help companies evaluate and develop strategies from 2022 to 2027.

Who are the Major Market Companies?          

Companies are  implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market

Abbott- The company offers drugs such as Ritonavir.

Our market growth and forecasting report includes detailed analyses of the market’s competitive landscape and offers information on 20 market companies, including :

  • AbbVie Inc.
  • Alpha Pharma
  • Aspen Pharmacare Holdings Ltd.
  • AstraZeneca Plc
  • Aurobindo Pharma Ltd.
  • Avacare Health
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Hetero Labs Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • SSI Diagnostica AS
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theratechnologies Inc.
  • Viatris Inc.

Qualitative and quantitative analysis of Companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize Companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize Companies as dominant, leading, strong, tentative, and weak.

Market Segmentation

The market share by the reverse transcriptase inhibitors segment will be significant during the forecast period. Reverse transcriptase inhibitors are pharmaceutical drugs used to treat and manage HIV. They belong to the anti-retroviral class of drugs. Reverse transcriptase inhibitors are further classified into two types, namely nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI). The large-scale availability of NRTIs and NNRTIs for HIV treatment is responsible for the favorable growth of this segment.

Get a glance at the market contribution of various segments Request a PDF Sample

The reverse transcriptase inhibitors segment showed a gradual increase in market share with USD 679.84 million in 2017 and will continue to grow by 2021. Some of the antiviral drugs used in anti-retroviral therapy include efavirenz, etravirine, and nevirapine, among others. Furthermore, the high use of NNRTI drugs among children and adults and growing R&D activities are expected to drive the growth of the reverse transcriptase inhibitors segment during the forecast period. Furthermore, our report provides a brief analysis of the historical and forecast market share and their segments along with the reasons for growth from 2017 to 2027.

The growth of this segment is primarily attributed to the increasing adoption of HIV treatment drugs in Africa, which is driven by an increase in the demand for HIV treatment drugs.

Market Analyst Overview

The Market sees significant advancements through pharmaceutical industry efforts in research and development, resulting in innovative therapies targeting drug-resistant HIV. Clinical trials, particularly Phase 3 programs for drugs like Islatravir and Doravirine, drive progress in combination therapies. Despite economic challenges and undiagnosed cases, international programs and organizations focus on HIV prevention, treatment, and care.

Deloitte's report highlights the high return on investment despite the cost of developing new drugs. Pharmaceutical companies expand distribution channels to address the prevalence of HIV infections, emphasizing therapeutic drugs' efficacy. This concerted effort underscores the commitment to combat HIV/AIDS in Africa, driving the market's growth and improving patient outcomes.

Segment Overview

Our market growth analysis report forecasts revenue and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by drug class, route of administration, and geography.

  • Drug Class Outlook (USD Million, 2017 - 2027)
    • Reverse transcriptase inhibitors
    • Protease inhibitors
    • Integrase inhibitors
    • Fusion inhibitors
    • Coreceptor antagonists 
  • Route of Administration Outlook (USD Million, 2017 - 2027)
    • Oral drugs
    • Injectable drugs
  • Geography Outlook (USD Million, 2017 - 2027)
    • South Africa
    • Nigeria 
    • Kenya 
    • Uganda 
    • Rest of Africa

HIV Treatment Drugs Market in Africa Scope

Report Coverage

Details

Page number

150

Base year

2022

Historical year

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 3.76%

Market growth 2023-2027

USD 321.6 million

Market structure

Fragmented

YoY growth (%)

3.5

Competitive landscape

Leading companies, Competitive Strategies, Consumer engagement scope

Key companies profiled

Abbott Laboratories, AbbVie Inc., Alpha Pharma, Aspen Pharmacare Holdings Ltd., AstraZeneca Plc, Aurobindo Pharma Ltd., Avacare Health, Boehringer Ingelheim International GmbH, Cipla Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Labs Ltd., Johnson & Johnson, Merck & Co. Inc., SSI Diagnostica AS, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Theratechnologies Inc., and Viatris Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the market between 2023 and 2027
  • Precise estimation of the size of the market and its contribution to the parent market.
  • Accurate predictions about  upcoming trends and changes in consumer behavior
  • A thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive details of factors that will challenge the growth of companies operating in the market

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Country Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Africa - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Regional - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Africa: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Regional - Market size and forecast 2022-2027 ($ million)

    4 Historic Market Size

    • 4.1 HIV treatment drugs market in Africa 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on HIV treatment drugs market in Africa 2017 - 2021 ($ million)
    • 4.2 Drug Class Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Drug Class Segment 2017 - 2021 ($ million)
    • 4.3 Route Of Administration Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Route Of Administration Segment 2017 - 2021 ($ million)
    • 4.4 Country Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 22: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 23: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 24: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 25: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 26: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 27: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 28: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Drug Class

    • 6.1 Market segments
      • Exhibit 29: Chart on Drug Class - Market share 2022-2027 (%)
      • Exhibit 30: Data Table on Drug Class - Market share 2022-2027 (%)
    • 6.2 Comparison by Drug Class
      • Exhibit 31: Chart on Comparison by Drug Class
      • Exhibit 32: Data Table on Comparison by Drug Class
    • 6.3 Reverse transcriptase inhibitors - Market size and forecast 2022-2027
      • Exhibit 33: Chart on Reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 34: Data Table on Reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Chart on Reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%)
      • Exhibit 36: Data Table on Reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%)
    • 6.4 Protease inhibitors - Market size and forecast 2022-2027
      • Exhibit 37: Chart on Protease inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 38: Data Table on Protease inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Chart on Protease inhibitors - Year-over-year growth 2022-2027 (%)
      • Exhibit 40: Data Table on Protease inhibitors - Year-over-year growth 2022-2027 (%)
    • 6.5 Integrase inhibitors - Market size and forecast 2022-2027
      • Exhibit 41: Chart on Integrase inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 42: Data Table on Integrase inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Chart on Integrase inhibitors - Year-over-year growth 2022-2027 (%)
      • Exhibit 44: Data Table on Integrase inhibitors - Year-over-year growth 2022-2027 (%)
    • 6.6 Fusion inhibitors - Market size and forecast 2022-2027
      • Exhibit 45: Chart on Fusion inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 46: Data Table on Fusion inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 47: Chart on Fusion inhibitors - Year-over-year growth 2022-2027 (%)
      • Exhibit 48: Data Table on Fusion inhibitors - Year-over-year growth 2022-2027 (%)
    • 6.7 Coreceptor antagonists - Market size and forecast 2022-2027
      • Exhibit 49: Chart on Coreceptor antagonists - Market size and forecast 2022-2027 ($ million)
      • Exhibit 50: Data Table on Coreceptor antagonists - Market size and forecast 2022-2027 ($ million)
      • Exhibit 51: Chart on Coreceptor antagonists - Year-over-year growth 2022-2027 (%)
      • Exhibit 52: Data Table on Coreceptor antagonists - Year-over-year growth 2022-2027 (%)
    • 6.8 Market opportunity by Drug Class
      • Exhibit 53: Market opportunity by Drug Class ($ million)

    7 Market Segmentation by Route of Administration

    • 7.1 Market segments
      • Exhibit 54: Chart on Route of Administration - Market share 2022-2027 (%)
      • Exhibit 55: Data Table on Route of Administration - Market share 2022-2027 (%)
    • 7.2 Comparison by Route of Administration
      • Exhibit 56: Chart on Comparison by Route of Administration
      • Exhibit 57: Data Table on Comparison by Route of Administration
    • 7.3 Oral drugs - Market size and forecast 2022-2027
      • Exhibit 58: Chart on Oral drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 59: Data Table on Oral drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 60: Chart on Oral drugs - Year-over-year growth 2022-2027 (%)
      • Exhibit 61: Data Table on Oral drugs - Year-over-year growth 2022-2027 (%)
    • 7.4 Injectable drugs - Market size and forecast 2022-2027
      • Exhibit 62: Chart on Injectable drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 63: Data Table on Injectable drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 64: Chart on Injectable drugs - Year-over-year growth 2022-2027 (%)
      • Exhibit 65: Data Table on Injectable drugs - Year-over-year growth 2022-2027 (%)
    • 7.5 Market opportunity by Route of Administration
      • Exhibit 66: Market opportunity by Route of Administration ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 67: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 68: Chart on Market share by geography - 2022-2027 (%)
      • Exhibit 69: Data Table on Market share by geography - 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 70: Chart on Geographic comparison
      • Exhibit 71: Data Table on Geographic comparison
    • 9.3 South Africa - Market size and forecast 2022-2027
      • Exhibit 72: Chart on South Africa - Market size and forecast 2022-2027 ($ million)
      • Exhibit 73: Data Table on South Africa - Market size and forecast 2022-2027 ($ million)
      • Exhibit 74: Chart on South Africa - Year-over-year growth 2022-2027 (%)
      • Exhibit 75: Data Table on South Africa - Year-over-year growth 2022-2027 (%)
    • 9.4 Nigeria - Market size and forecast 2022-2027
      • Exhibit 76: Chart on Nigeria - Market size and forecast 2022-2027 ($ million)
      • Exhibit 77: Data Table on Nigeria - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Chart on Nigeria - Year-over-year growth 2022-2027 (%)
      • Exhibit 79: Data Table on Nigeria - Year-over-year growth 2022-2027 (%)
    • 9.5 Kenya - Market size and forecast 2022-2027
      • Exhibit 80: Chart on Kenya - Market size and forecast 2022-2027 ($ million)
      • Exhibit 81: Data Table on Kenya - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Chart on Kenya - Year-over-year growth 2022-2027 (%)
      • Exhibit 83: Data Table on Kenya - Year-over-year growth 2022-2027 (%)
    • 9.6 Uganda - Market size and forecast 2022-2027
      • Exhibit 84: Chart on Uganda - Market size and forecast 2022-2027 ($ million)
      • Exhibit 85: Data Table on Uganda - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Chart on Uganda - Year-over-year growth 2022-2027 (%)
      • Exhibit 87: Data Table on Uganda - Year-over-year growth 2022-2027 (%)
    • 9.7 Rest of Africa - Market size and forecast 2022-2027
      • Exhibit 88: Chart on Rest of Africa - Market size and forecast 2022-2027 ($ million)
      • Exhibit 89: Data Table on Rest of Africa - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Chart on Rest of Africa - Year-over-year growth 2022-2027 (%)
      • Exhibit 91: Data Table on Rest of Africa - Year-over-year growth 2022-2027 (%)
    • 9.8 Market opportunity by geography
      • Exhibit 92: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 93: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 94: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 95: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 96: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 97: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 98: Matrix on vendor position and classification
            • 12.3 Abbott Laboratories
              • Exhibit 99: Abbott Laboratories - Overview
              • Exhibit 100: Abbott Laboratories - Business segments
              • Exhibit 101: Abbott Laboratories - Key news
              • Exhibit 102: Abbott Laboratories - Key offerings
              • Exhibit 103: Abbott Laboratories - Segment focus
            • 12.4 AbbVie Inc.
              • Exhibit 104: AbbVie Inc. - Overview
              • Exhibit 105: AbbVie Inc. - Product / Service
              • Exhibit 106: AbbVie Inc. - Key offerings
            • 12.5 Alpha Pharma
              • Exhibit 107: Alpha Pharma - Overview
              • Exhibit 108: Alpha Pharma - Product / Service
              • Exhibit 109: Alpha Pharma - Key offerings
            • 12.6 Aspen Pharmacare Holdings Ltd.
              • Exhibit 110: Aspen Pharmacare Holdings Ltd. - Overview
              • Exhibit 111: Aspen Pharmacare Holdings Ltd. - Business segments
              • Exhibit 112: Aspen Pharmacare Holdings Ltd. - Key offerings
              • Exhibit 113: Aspen Pharmacare Holdings Ltd. - Segment focus
            • 12.7 AstraZeneca Plc
              • Exhibit 114: AstraZeneca Plc - Overview
              • Exhibit 115: AstraZeneca Plc - Product / Service
              • Exhibit 116: AstraZeneca Plc - Key news
              • Exhibit 117: AstraZeneca Plc - Key offerings
            • 12.8 Aurobindo Pharma Ltd.
              • Exhibit 118: Aurobindo Pharma Ltd. - Overview
              • Exhibit 119: Aurobindo Pharma Ltd. - Product / Service
              • Exhibit 120: Aurobindo Pharma Ltd. - Key offerings
            • 12.9 Avacare Health
              • Exhibit 121: Avacare Health - Overview
              • Exhibit 122: Avacare Health - Product / Service
              • Exhibit 123: Avacare Health - Key offerings
            • 12.10 Cipla Ltd.
              • Exhibit 124: Cipla Ltd. - Overview
              • Exhibit 125: Cipla Ltd. - Business segments
              • Exhibit 126: Cipla Ltd. - Key news
              • Exhibit 127: Cipla Ltd. - Key offerings
              • Exhibit 128: Cipla Ltd. - Segment focus
            • 12.11 F. Hoffmann La Roche Ltd.
              • Exhibit 129: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 130: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 131: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 132: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 133: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.12 Gilead Sciences Inc.
              • Exhibit 134: Gilead Sciences Inc. - Overview
              • Exhibit 135: Gilead Sciences Inc. - Product / Service
              • Exhibit 136: Gilead Sciences Inc. - Key news
              • Exhibit 137: Gilead Sciences Inc. - Key offerings
            • 12.13 GlaxoSmithKline Plc
              • Exhibit 138: GlaxoSmithKline Plc - Overview
              • Exhibit 139: GlaxoSmithKline Plc - Business segments
              • Exhibit 140: GlaxoSmithKline Plc - Key offerings
              • Exhibit 141: GlaxoSmithKline Plc - Segment focus
            • 12.14 Merck and Co. Inc.
              • Exhibit 142: Merck and Co. Inc. - Overview
              • Exhibit 143: Merck and Co. Inc. - Business segments
              • Exhibit 144: Merck and Co. Inc. - Key news
              • Exhibit 145: Merck and Co. Inc. - Key offerings
              • Exhibit 146: Merck and Co. Inc. - Segment focus
            • 12.15 Sun Pharmaceutical Industries Ltd.
              • Exhibit 147: Sun Pharmaceutical Industries Ltd. - Overview
              • Exhibit 148: Sun Pharmaceutical Industries Ltd. - Product / Service
              • Exhibit 149: Sun Pharmaceutical Industries Ltd. - Key offerings
            • 12.16 Theratechnologies Inc.
              • Exhibit 150: Theratechnologies Inc. - Overview
              • Exhibit 151: Theratechnologies Inc. - Product / Service
              • Exhibit 152: Theratechnologies Inc. - Key offerings
            • 12.17 Viatris Inc.
              • Exhibit 153: Viatris Inc. - Overview
              • Exhibit 154: Viatris Inc. - Business segments
              • Exhibit 155: Viatris Inc. - Key offerings
              • Exhibit 156: Viatris Inc. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 157: Inclusions checklist
                • Exhibit 158: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 159: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 160: Research methodology
                • Exhibit 161: Validation techniques employed for market sizing
                • Exhibit 162: Information sources
              • 13.5 List of abbreviations
                • Exhibit 163: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              hiv treatment drugs market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis